Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 30 of 88« First...1020...2829303132...405060...Last »

Keryx says anemia drug succeeds in study of kidney patients

Keryx Biopharmaceuticals Inc. said its drug to treat iron deficiency anemia in chronic kidney disease patients not yet requiring dialysis met the goals of a late-stage clinical trial.

Read More »

Alder drug to prevent migraines successful in mid-stage study

Alder BioPharmaceuticals Inc. said its injection to prevent migraines had met the main goal in a mid-stage study.

Read More »

A Peek into Pfizer’s R&D Process: from Molecule to Medicine

There’s a slightly hollow feeling about the faded business park which was once home to Pfizer’s bustling R&D community and supported thousands of jobs in the nearby town of Sandwich.

Read More »

Pharma Engagement Strategy with IDNs – Embedding in Clinical Pathways

While every medical case is unique, payers and providers are attempting to standardize treatment since unnecessary variation is a major source of growing costs.

Read More »

Seven Potential Blockbuster Drugs May Hit The Market This Year

The analysts at Thomson Reuters have consulted their crystal balls and come up with seven drugs coming out this year that will likely hit blockbuster status – defined as marking more than $1 billion annually.

Read More »

Bay State’s FORUM Pharma Lays Off 89 After Two Failed Clinical Trials

March 25, 2016 By Mark Terry, BioSpace.com Breaking News Staff   Waltham, Mass.-based FORUM Pharmaceuticals, in light of two Phase III trial disappointments, is laying off half its staff and restructuring the company. In September 2015, the U.S. Food and Drug Administration (FDA) advised FORUM to halt its clinical trials of encenicline for Alzheimer’s disease. […]

Read More »

Many patients with high stroke risk do not get needed blood thinners

Patients who have a heart rhythm disorder that can come with a high risk of stroke often don’t receive blood-thinning medications that can make this complication less likely, a U.S. study suggests. Researchers studied almost 430,000 people with a condition known as atrial fibrillation, an irregular rapid heartbeat that can lead to stoke, heart failure […]

Read More »

Portola’s long-acting blood thinner misses main study goal

Portola Pharmaceuticals Inc said data showed its oral anticoagulant missed the main goal of preventing blood clots in acutely ill patients in a late-stage study. The company’s shares fell 30 percent to a two-year low of $20.00 in early trading. Portola’s betrixaban, designed for the prevention of venous thromboembolism (VTE), or blood clots, was tested […]

Read More »

Regeneron and Bayer To Jointly Develop Novel Combination Therapy for Eye Diseases

TARRYTOWN, N.Y., March 24, 2016 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Bayer will jointly develop a combination therapy of the angiopoietin2 (Ang2) antibody nesvacumab and the vascular endothelial growth factor (VEGF) trap aflibercept, for the treatment of serious eye diseases. Two separate Phase 2 clinical studies are evaluating the combination therapy as a co-formulated […]

Read More »

AstraZeneca heart drug fails in key stroke trial

AstraZeneca’s heart drug Brilinta has failed to help stroke patients as hoped in a big clinical trial, dealing a blow to the company’s expectations that the medicine could rack up annual sales of $3.5 billion by 2023.   The trial found the blood-thinner was not significantly better than aspirin, the current standard of care, in […]

Read More »

Sanofi, Regeneron unveil positive Praluent cholesterol study

French drugmaker Sanofi and U.S. partner Regeneron said a late-stage study of their Praluent injection showed it reduced the need for patients with an inherited form of high cholesterol to have bad cholesterol removed from their blood.   “This is the first time a PCSK9 inhibitor has shown in a clinical study that it reduced […]

Read More »

Fitness trackers bad at keeping tabs on how much energy we burn

Fitness trackers may be a trendy way to monitor every step we take, but these gadgets are actually pretty bad at keeping tabs on how much energy we burn, a new study suggests.

Read More »

BioMarin drug fails to show inattention, mood benefit in study

BioMarin’s genetic disorder drug met the study’s main goal of reducing a toxic buildup of an amino acid, but did not show enough benefit in related inattention and mood complications.

Read More »

J&J psoriasis drug Stelara eases Crohn’s disease in second trial

Johnson & Johnson’s Stelara psoriasis drug has shown effectiveness against Crohn’s disease in a second late-stage trial, bolstering prospects of its approval for the additional use.

Read More »

Study strengthens Zika-microcephaly link, women and babies at risk

Thousands of pregnant women caught in the outbreak of the mosquito-borne virus spreading from Brazil risk having a baby with the birth defect microcephaly, according to study results.

Read More »

Gilead Shuts Down Six Zydelig Trials Following EMA Review

Gilead Sciences halted six trials for its cancer drug Zydelig following concerns of adverse effects and deaths.

Read More »

Experts urge more cautious dosing after fatal French drug trial

Researchers should be more cautious in dosing experimental medicines in early human trials, even when drugs are thought to be low risk, experts reviewing a French clinical study that left one person dead said on Wednesday.   The volunteer died and five others became seriously ill in January after being given high doses of a […]

Read More »

Gum disease may signal faster Alzheimer’s decline

For people with Alzheimer’s disease, having gum disease is tied to faster cognitive decline, according to a new study. “What we have shown is that regardless of the severity of dementia (within this mild to moderate impaired group) that patients with more severe gum disease are declining more rapidly,” said senior author Clive Holmes of […]

Read More »

John Grisham book turns spotlight on futuristic cancer treatment

A new book by bestselling author John Grisham is giving new impetus to a handful of companies striving to develop what could be a trailblazing treatment for cancer and AD.

Read More »

Top NFL official acknowledges link between football and brain disease

A top NFL official acknowledged for the first time on Monday a link between football-related concussions and chronic traumatic encephalopathy (CTE).

Read More »

Page 30 of 88« First...1020...2829303132...405060...Last »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

April 2018 Focus: Agency Profiles, Manny Awards and Annual Review

Subscribe

Ad Right Bottom

Main Navigation